TWI597071B - 包含雷公藤內酯醇衍生物之組合物及其用途 - Google Patents

包含雷公藤內酯醇衍生物之組合物及其用途 Download PDF

Info

Publication number
TWI597071B
TWI597071B TW103109891A TW103109891A TWI597071B TW I597071 B TWI597071 B TW I597071B TW 103109891 A TW103109891 A TW 103109891A TW 103109891 A TW103109891 A TW 103109891A TW I597071 B TWI597071 B TW I597071B
Authority
TW
Taiwan
Prior art keywords
triptolide
composition
oil
group
sodium
Prior art date
Application number
TW103109891A
Other languages
English (en)
Chinese (zh)
Other versions
TW201440812A (zh
Inventor
安金華
柏恩德 史利傑
強Ｍ 費德勒
約翰Ｈ 馬瑟
Original Assignee
美國泛華醫藥公司
玫洛斯有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美國泛華醫藥公司, 玫洛斯有限責任公司 filed Critical 美國泛華醫藥公司
Publication of TW201440812A publication Critical patent/TW201440812A/zh
Application granted granted Critical
Publication of TWI597071B publication Critical patent/TWI597071B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
TW103109891A 2013-03-15 2014-03-17 包含雷公藤內酯醇衍生物之組合物及其用途 TWI597071B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361794926P 2013-03-15 2013-03-15
PCT/US2014/030041 WO2014145303A1 (en) 2013-03-15 2014-03-15 Intravenous emulsions of triptolide as immunomodulators and anticancer agents i

Publications (2)

Publication Number Publication Date
TW201440812A TW201440812A (zh) 2014-11-01
TWI597071B true TWI597071B (zh) 2017-09-01

Family

ID=51537944

Family Applications (1)

Application Number Title Priority Date Filing Date
TW103109891A TWI597071B (zh) 2013-03-15 2014-03-17 包含雷公藤內酯醇衍生物之組合物及其用途

Country Status (7)

Country Link
US (1) US20160038454A1 (enExample)
EP (1) EP2968140A4 (enExample)
JP (1) JP2016515530A (enExample)
CN (1) CN105263475A (enExample)
HK (1) HK1219228A1 (enExample)
TW (1) TWI597071B (enExample)
WO (1) WO2014145303A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2881878T3 (es) * 2015-09-11 2021-11-30 Ys Ac Co Ltd Composición para el tratamiento del cáncer que combina el anticuerpo anti-CD26 y otro antineoplásico
US10342797B2 (en) 2016-03-13 2019-07-09 LivePet, LLC Solubility of therapeutic agents
CN107663225A (zh) * 2016-07-29 2018-02-06 欣凯医药化工中间体（上海）有限公司 一种氟代雷公藤内酯醇内酯环衍生物
CN108530511B (zh) * 2017-03-02 2021-06-22 欣凯医药化工中间体（上海）有限公司 一种c19-酰基化雷公藤甲素衍生物
CN106946975B (zh) * 2017-03-16 2020-08-14 上海天氏利医药科技有限公司 一种雷公藤甲素衍生物及其制备方法与制剂
CN106994129A (zh) * 2017-05-15 2017-08-01 王晓辉 雷公藤甲素及其衍生物在制备治疗和/或预防肺损伤疾病的药物中的应用
WO2018222351A1 (en) * 2017-05-27 2018-12-06 Pharmagenesis, Inc. Triptolide lactone derivatives as immunomodulators and anticancer agents
WO2019173526A1 (en) * 2018-03-07 2019-09-12 Andrew Xian Chen Aqueous formulations for insoluble drugs
CN109771430A (zh) * 2019-03-15 2019-05-21 大连大学 甘氨胆酸在制备抗肿瘤药物中的应用
CN111494319A (zh) * 2020-06-15 2020-08-07 沈阳药科大学 雷公藤甲素复方组合物及其制备方法与应用
CN115466269A (zh) * 2021-06-11 2022-12-13 复旦大学 一种胆碱碳酸酯类前药及其制备方法和应用
CN114569554A (zh) * 2022-03-01 2022-06-03 福建省医学科学研究院 一种肿瘤靶向性雷公藤内酯醇乳液及其制备方法
CN114831962A (zh) * 2022-04-29 2022-08-02 福建省医学科学研究院 一种雷公藤内酯醇固体脂质纳米粒及其滴丸的制备方法
CN117088935A (zh) * 2022-05-20 2023-11-21 上海维洱生物医药科技有限公司 一种雷公藤甲素木蜡酸酯及其脂质体与制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3631795A (en) * 1994-09-15 1996-03-29 Pharmagenesis, Inc. Composition and method for immunotherapy
JP2006513209A (ja) * 2002-12-17 2006-04-20 ファーマジェネシス， インコーポレイテッド 免疫調節因子および抗癌剤としてのトリプトライド誘導体
US7863464B2 (en) * 2004-03-02 2011-01-04 Pharmagenesis, Inc. Triptolide lactone ring derivatives as immunomodulators and anticancer agents
AP2626A (en) * 2005-08-29 2013-03-26 Sepsicure Llc Method for treatment or prevention of conditions caused by gram-positive bacteria
CN101485629B (zh) * 2008-01-16 2013-01-23 沈阳药科大学 一种给药系统及其制备方法
TW201138782A (en) * 2010-04-26 2011-11-16 Besins Healthcare Lu Sarl Low-oil pharmaceutical emulsion compositions comprising progestogen
CN102793674B (zh) * 2011-05-26 2014-11-26 澳门科技大学 一种雷公藤甲素固体脂质纳米颗粒及其制备方法和应用
CN102552137B (zh) * 2012-02-22 2013-04-10 福建医科大学 雷公藤内酯醇脂肪乳注射剂及其制备方法

Also Published As

Publication number Publication date
WO2014145303A1 (en) 2014-09-18
HK1219228A1 (zh) 2017-03-31
US20160038454A1 (en) 2016-02-11
CN105263475A (zh) 2016-01-20
EP2968140A4 (en) 2016-11-16
TW201440812A (zh) 2014-11-01
JP2016515530A (ja) 2016-05-30
EP2968140A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
TWI597071B (zh) 包含雷公藤內酯醇衍生物之組合物及其用途
CN111225665B (zh) 大环免疫调节剂
KR102500181B1 (ko) 암-표적화 약물 운송수단으로서의 인지질 에테르 유사체
KR101739800B1 (ko) 안드로겐 수용체 조절제의 에스터 유도체 및 그의 이용 방법
JP2010512397A (ja) アンサマイシン製剤およびその使用法
JP5057966B2 (ja) 免疫調節剤および抗癌剤としてのトリプトライドラクトン環誘導体
JP6803898B2 (ja) オメガ−３脂肪酸およびトマトリコペンを含む抗炎症性相乗的組み合わせ
WO2018157874A1 (zh) 一种双氢青蒿素二倍体衍生物、其药物组合物及应用
CA3130349A1 (en) Lipid prodrugs of jak inhibitors and uses thereof
JP2011525486A (ja) 活動亢進性免疫系を治療するためのシクロリグナンの使用
CN104945318A (zh) 羟基吡啶酮衍生物、其药物组合物及其用于治疗增生性疾病的治疗用途
CA3111403A1 (en) Matter of composition, synthesis, formulation and application of fl118 platform positions 7 and 9-derived analogues for treatment of human disease
WO2014201111A1 (en) Treatment of mtor hyperactive related diseases and disorders
TW202010502A (zh) 包含糖皮質激素受體拮抗劑之固體形式與調配物及其用途
TW202039439A (zh) ４（１ｈ）－奎諾酮衍生物及其用途
JP2006513209A (ja) 免疫調節因子および抗癌剤としてのトリプトライド誘導体
EP3568138B1 (en) Compositions and methods for the treatment of myelin related and inflammation related diseases or disorders
CN111620815B (zh) 手性氯喹、羟氯喹和其衍生物及其制备方法与用途
JP2023517736A (ja) 免疫調節剤
UA121315C2 (uk) Макроциклічні інгібітори кінази rip2
CN111202737B (zh) 雷公藤红素酰胺衍生物在制备治疗自身性免疫疾病药物的应用
TWI664174B (zh) 雜環化合物及其用途
WO2004026298A1 (en) Derivatives of triptolide having high immunosuppressive effect and high water solubility, and uses thereof
KR20210040803A (ko) 신규 화합물 및 이의 자가면역질환 치료 용도
CN104080449A (zh) 4，9-二羟基-萘并[2，3-b]呋喃脂肪酸酯衍生物的纳米颗粒水悬液的制备方法